Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.25 (
MEKK1
)
1,856
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We investigated the mechanisms by which nitric oxide (NO) from an NO donor (
DETA
/NO) regulates proliferation of pheochromocytoma PC12 cells. The NO donor stimulated proliferation at low concentrations, but reversibly and completely inhibited proliferation at higher concentrations. The stimulation (but not the inhibition) of proliferation was apparently due to NO stimulation of soluble guanylate cyclase to produce cGMP, as it was prevented by a specific cyclase inhibitor (ODQ), and replicated by a cell-permeable form of cGMP. The NO-induced cytostasis was not reversed by inhibitors of
MEK kinase
or poly(ADP-ribose)polymerase, or by treatments that bypass inhibition of ribonucleotide reductase or ornithine decarboxylase. Cytostatic concentrations of
DETA
/NO strongly inhibited respiration of PC12 cells, and specific respiratory inhibitors (rotenone, myxothiazol, or azide) caused complete cytostasis. Uridine and pyruvate reversed the cytostasis induced by the specific respiratory inhibitors, but not that induced by
DETA
/NO. However, the combination of uridine, pyruvate, and N-acetyl-cysteine did reverse
DETA
/NO-induced cytostasis.
DETA
/NO strongly and progressively inhibited glycolysis measured by glucose consumption, lactate production, and ATP level, and a specific glycolytic inhibitor (5 mM 2-deoxy-d-glucose) caused complete cytostasis. Our results indicate that NO at low concentrations increases cell proliferation via cGMP, while high concentrations of NO block proliferation via inhibition of both glycolysis and respiration, causing energy depletion.
...
PMID:Nitric oxide stimulates PC12 cell proliferation via cGMP and inhibits at higher concentrations mainly via energy depletion. 1630 Sep 73
The aim of the present investigation was to characterize the role of the MAPK kinase kinase-1 (
MEKK
-1) in stress-induced cell death of insulin producing cells. We observed that transient overexpression of the wild type
MEKK
-1 protein in the insulin-producing cell lines RIN-5AH and betaTC-6 increased c-Jun N-terminal kinase (JNK) phosphorylation and augmented cell death induced by diethylenetriamine/nitroso-1-propylhydrazino)-1-propanamine (
DETA
/NO), streptozotocin (STZ), and hydrogen peroxide (H2O2). Furthermore,
DETA
/NO or STZ induced a rapid threonine phosphorylation of
MEKK
-1. Silencing of
MEKK
-1 gene expression in betaTC-6 and human dispersed islet cells, using in vitro-generated diced small interfering RNA, resulted in protection from
DETA
/NO, STZ, H2O2, and tunicamycin induced cell death. Moreover, in
DETA
/NO-treated cells diced small interfering RNA-mediated down-regulation of
MEKK
-1 resulted in decreased activation of JNK but not p38 and ERK. Inhibition of JNK by treatment with SP600125 partially protected against
DETA
/NO- or STZ-induced cell death. In summary, our results support an essential role for
MEKK
-1 in JNK activation and stress-induced beta-cell death. Increased understanding of the signaling pathways that augment or diminish beta-cell
MEKK
-1 activity may aid in the generation of novel therapeutic strategies in the treatment of type 1 diabetes.
...
PMID:The MAPK kinase kinase-1 is essential for stress-induced pancreatic islet cell death. 1830 48